IPSEN |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 123.6 EUR | +1.15% |
|
+2.15% | +14.55% |
| May. 14 | Ipsen: share price up, analyst raises target | CF |
| May. 14 | IPSEN : Barclays raises its target price | CF |
| Sales 2024 * | 3.47B 3.75B | Sales 2025 * | 3.71B 4.01B | Capitalization | 10.21B 11.04B |
|---|---|---|---|---|---|
| Net income 2024 * | 648M 701M | Net income 2025 * | 721M 780M | EV / Sales 2024 * | 2.79 x |
| Net cash position 2024 * | 545M 589M | Net cash position 2025 * | 1.19B 1.29B | EV / Sales 2025 * | 2.43 x |
| P/E ratio 2024 * |
15.9
x | P/E ratio 2025 * |
14.3
x | Employees | 5,325 |
| Yield 2024 * |
0.99% | Yield 2025 * |
0.98% | Free-Float | 41.52% |
More Fundamentals
* Assessed data
More news
Latest transcript on Ipsen
More press releases
More news
| 1 day | +1.15% | ||
| 1 week | +2.15% | ||
| Current month | +8.33% | ||
| 1 month | +9.87% | ||
| 3 months | +18.05% | ||
| 6 months | +18.28% | ||
| Current year | +14.55% |
1 week
119.70
124.50
1 month
111.10124.50
Current year
99.70124.50
1 year
99.70130.70
3 years
77.00130.70
5 years
34.20130.70
10 years
31.50155.95
| Managers | Title | Age | Since |
|---|---|---|---|
David Loew
CEO | Chief Executive Officer | 57 | 20-06-30 |
| Director of Finance/CFO | 55 | 14-11-02 | |
| Chairman | 66 | 10-11-21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Margaret Liu
BRD | Director/Board Member | 66 | 17-06-06 |
Karen Witts
BRD | Director/Board Member | 61 | 22-01-20 |
Michèle Ollier
BRD | Director/Board Member | 65 | 15-05-26 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.83% | 2 M€ | +10.66% | ||
| 0.43% | 242 M€ | +9.68% | ||
| 0.31% | 3 M€ | +9.95% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-23 | 123.6 | +1.15% | 81,203 |
| 24-05-22 | 122.2 | +0.74% | 78,745 |
| 24-05-21 | 121.3 | -0.33% | 54,434 |
| 24-05-20 | 121.7 | +0.75% | 40,317 |
| 24-05-17 | 120.8 | -0.49% | 51,089 |
Real-time Euronext Paris, May 23, 2024 at 11:35 am EDT
More quotes
Ipsen specialises in the research, development, manufacture and marketing of specialty medicines. Net sales by therapeutic area break down as follows:
- oncology (75.2%);
- neuroscience (21.1%);
- rare diseases (3.7%).
At the end of 2023, the group had 4 research and development centres located in France, the United Kingdom, the United States and China, and 4 manufacturing sites worldwide.
Net sales are distributed geographically as follows: Europe (40.2%), North America (33.3%) and other (26.5%).
Sector
Pharmaceuticals
Calendar
2024-05-28
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
123.6
EUR
Average target price
126.4
EUR
Spread / Average Target
+2.27%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +14.55% | 10.94B | |
| +38.69% | 723B | |
| +34.28% | 595B | |
| -4.49% | 369B | |
| +20.24% | 332B | |
| +2.12% | 282B | |
| +17.02% | 244B | |
| +9.31% | 208B | |
| -5.07% | 205B | |
| -0.35% | 168B |
- Stock Market
- Equities
- IPN Stock
